Physician Demo

Receive patient matches, access emerging therapies, and view demand analytics

Patient Match Notifications

1 New

Patient with ALS requesting BIOIO-1001 consultation

12/20/2024, 10:30:00 AM

NEW

Patient with T2D interested in GLP-1 sensitizer combination

12/19/2024, 2:15:00 PM

Patient Profile

Primary Condition

Amyotrophic Lateral Sclerosis (ALS)
ICD-10: G12.21 • Severity: moderate

Current Medications

  • Riluzole
  • Edaravone

Key Biomarkers

Triglycerides:85 mg/dL (Low)
Glucose:92 mg/dL
Weight:165 lbs (Declining)

Alternative Therapy

BIOIO-1001

89% Match

BIOIO • Phase 1

Mechanism

NMNAT1/NAD+/SIRT3 pathway activation - dual insulin and GLP-1 sensitizer

Why This Match?

Patient's low triglyceride level (85 mg/dL) is problematic in ALS. BIOIO-1001 paradoxically raises triglycerides in ALS models, improving energy metabolism in this nutrient-deficient disease state. Animal studies show 28% survival extension.

Access Pathway

Available via Montana's SB 535 right-to-try legislation. Patient would need to travel to MT for initial consultation and prescription.

Emerging Therapy Demand Analytics

See what your patient population is searching for and requesting

342
Patients in your area seeking candidate therapies
+45%
Growth in right-to-try requests this quarter
MT
Nearest right-to-try state for your patient population

Top Requested Therapy Categories

ALS

Metabolic modulators

#1
Patient Demand:
127
Physician Interest:
45
Avg Severity:
2.4/3

Type 2 Diabetes

GLP-1 sensitizers

#2
Patient Demand:
2341
Physician Interest:
189
Avg Severity:
1.8/3

Diabetic Neuropathy

Sphingolipid modulators

#3
Patient Demand:
876
Physician Interest:
92
Avg Severity:
2.1/3

Expand Your Practice Capabilities

  • ✓Offer cutting-edge therapies unavailable elsewhere
  • ✓Attract patients seeking novel treatment options
  • ✓Stay informed on emerging therapeutic developments
  • ✓Participate in right-to-try treatment pathways

How Avenir Supports You

  • →AI-powered matching sends you relevant patients automatically
  • →Detailed drug mechanisms and clinical data at your fingertips
  • →Simplified right-to-try regulatory compliance guidance
  • →Direct connection with biopharma companies for questions